UnknownNCT05644301
Minocycline or celecoxib versus placebo for immune-mediated depression
About this title
Read the official source — NCT05644301Medication studyAges 18–65Belgium
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Duffel and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 21, 2023
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 240
- Sponsor
- Universiteit Antwerpen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Belgium
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05644301
- Official title
Show the full official title
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Duffel · Brussels · Leuven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Universiteit Antwerpen.
Does this study involve medication?
Yes. The study involves medication, including Celecoxib, Minocyclin and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
